Streetwise Reports' Article Archives — August 2017 back to current month (11)

With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena (08/30/2017)

Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella.


Analyst Says Cell Therapy Company's Move Decreases Risk (08/23/2017)

A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk.


Medical Cannabis Innovator Set to Go Public (08/18/2017)

A licensed producer of medical cannabis in Canada will begin trading on the Canadian Securities Exchange on Aug. 21.


Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection (08/16/2017)

Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations.


'Keep a Close Eye On' This Regenerative Medicine Firm (08/16/2017)

In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."


Maxim Raises Target Price of Biotech Company (08/16/2017)

A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech.


Cell Therapy for Melanoma Impresses in
Phase 2

Positive clinical data for this U.S. company's immunotherapy for metastatic melanoma are both encouraging and impressive, says one analyst.


Over-the-Counter Treatments for Joint Pain and Women's Health Propel Company into New Markets (08/09/2017)

With the launch of its over-the-counter combination treatment for joint pain and new licensing agreements for feminine lubrication product Zestra, this San Diego-based company is expanding both its therapeutic and international reach.


Company Developing Cannabinoid-Based Drug Therapy for Concussions Completes Reverse Takeover (08/07/2017)

A drug developer working on a treatment for concussions expects to begin trading on the TSX Venture Exchange on Aug. 8.


This Just Changed Everything: Green Profits Are Being Unleashed (08/03/2017)

Kenneth Ameduri, founder of Crush the Street, discusses why he believes now is a good time to take advantage of cannabis investing opportunities.


Loan Provides Driver for Growth for Medical Device Firm (08/02/2017)

Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth.


More Archives

2024Apr Mar Feb Jan

2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes